BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11956127)

  • 21. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
    Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
    J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein D and platelet-derived growth factor-BB synergism mediates vascular smooth muscle cell migration.
    Leung WC; Lawrie A; Demaries S; Massaeli H; Burry A; Yablonsky S; Sarjeant JM; Fera E; Rassart E; Pickering JG; Rabinovitch M
    Circ Res; 2004 Jul; 95(2):179-86. PubMed ID: 15192024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells.
    Perkins RC; Broaddus VC; Shetty S; Hamilton S; Idell S
    Am J Respir Cell Mol Biol; 1999 Nov; 21(5):637-46. PubMed ID: 10536123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
    Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
    Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic Overexpression of Soluble Urokinase Receptor (uPAR) Suppresses Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR-/-) Mice.
    Larmann J; Jurk K; Janssen H; Müller M; Herzog C; Lorenz A; Schmitz M; Nofer JR; Theilmeier G
    PLoS One; 2015; 10(8):e0131854. PubMed ID: 26313756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M; Goretzki L; Pfeifer M; Mueller BM
    Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro.
    Taira K; Bujo H; Hirayama S; Yamazaki H; Kanaki T; Takahashi K; Ishii I; Miida T; Schneider WJ; Saito Y
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1501-6. PubMed ID: 11557679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmented urokinase receptor expression in atheroma.
    Noda-Heiny H; Daugherty A; Sobel BE
    Arterioscler Thromb Vasc Biol; 1995 Jan; 15(1):37-43. PubMed ID: 7749814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor through a post-transcriptional mechanism.
    Montuori N; Mattiello A; Mancini A; Santoli M; Taglialatela P; Caputi M; Rossi G; Ragno P
    FEBS Lett; 2001 Nov; 508(3):379-84. PubMed ID: 11728456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent.
    Tuck AB; Hota C; Chambers AF
    Breast Cancer Res Treat; 2001 Dec; 70(3):197-204. PubMed ID: 11804183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains.
    Poliakov AA; Mukhina SA; Traktouev DO; Bibilashvily RS; Gursky YG; Minashkin MM; Stepanova VV; Tkachuk VA
    J Recept Signal Transduct Res; 1999 Nov; 19(6):939-51. PubMed ID: 10533982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration.
    Li Y; Knisely JM; Lu W; McCormick LM; Wang J; Henkin J; Schwartz AL; Bu G
    J Biol Chem; 2002 Nov; 277(44):42366-71. PubMed ID: 12194987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.
    Kunigal S; Gondi CS; Gujrati M; Lakka SS; Dinh DH; Olivero WC; Rao JS
    Int J Oncol; 2006 Dec; 29(6):1349-57. PubMed ID: 17088972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
    Kiyan J; Smith G; Haller H; Dumler I
    Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    Ossowski L; Clunie G; Masucci MT; Blasi F
    J Cell Biol; 1991 Nov; 115(4):1107-12. PubMed ID: 1659573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH; Mazar A; Henkin J; Rabbani SA
    Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.